PRAC meeting highlights 2-5 September 2024

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring safety issues for human medicines.

The current PRAC highlights from the Sept 2024 meeting describes measures to minimise serious outcomes of known side effect with painkiller metamizole and outlines recommendations to minimise the risk of meningioma with medicines containing medroxyprogesterone acetate.